SFM
ITCI

Sphera Funds Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Sphera Funds Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-228,700
Closed -$5.87M – 120
2020
Q2 		$5.87M Buy
+228,700
New +$4.63M 0.55% 46
2019
Q3 		– Sell
-300,000
Closed -$3.89M – 106
2019
Q2 		$3.89M Hold
300,000
– – 0.53% 57
2019
Q1 		$3.65M Buy
+300,000
New +$3.83M 0.33% 70

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sphera Funds Management's ITCI Position: Q1 2016 in Review

Sphera Funds Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2016, closing a stake of 48,400 shares — an estimated $2.6M sold.

Sphera Funds Management first reported a position in ITCI in Q1 2014 and held it in 6 quarters. The position peaked at $4.22M in Q3 2015. 127 funds tracked by Wall St. Rank hold ITCI as of Q1 2016.

  • Sphera Funds Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2016 after selling out during the quarter.
  • Sphera Funds Management sold 48,400 Intra-Cellular Therapies Inc. shares in Q1 2016, an estimated $2.6M.
  • Sphera Funds Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2014 and held it in 6 quarters.
  • Sphera Funds Management's Intra-Cellular Therapies Inc. position peaked at $4.22M in Q3 2015.
  • 127 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2016.

Based on Sphera Funds Management's 13F filing for Q1 2016, filed 16 May 2016.